Bristol-Myers Squibb Partners To Expand Diabetes Franchise In China
This article was originally published in PharmAsia News
Executive Summary
With Glucophage and Onglyza already on the market, BMS plans to launch more products in China through partnerships to gain a share of the world’s largest diabetes market.
You may also be interested in...
Lyxumia As Fourth GLP-1 To Market? Not To Worry, Says Zealand CEO
The Danish biotech has partnerships with major players in several therapeutic areas, including a successful tie-up with Sanofi, and is looking to partner some of its other pipeline programs as well.
Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission
Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.
AstraZeneca, BMY To Target Disease Management And Primary Care Synergies With Amylin Acquisition
In acquiring Amylin at a hefty premium, Bristol-Myers Squibb and its partner AstraZeneca are highly optimistic about prospects for Amylin’s GLP-1 franchise, and also hope to leverage their existing infrastructure as their fledgling diabetes franchise struggles to meet expectations.